Affordable Access

deepdyve-link
Publisher Website

Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.

Authors
  • Stagno, Fabio
  • Vigneri, Paolo
  • Di Raimondo, Francesco
Type
Published Article
Journal
Leukemia Research
Publisher
Elsevier
Publication Date
Jul 01, 2012
Volume
36
Issue
7
Pages
803–803
Identifiers
DOI: 10.1016/j.leukres.2012.03.016
PMID: 22502918
Source
Medline
License
Unknown
Report this publication

Statistics

Seen <100 times